Floatz logo

Octreotide Pamoate

Severe Obesity

Hvidovre University HospitalPhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Severe Obesity cohort.

Asset / SponsorPhaseRating
Colesevelam
Hvidovre University Hospital
Phase 4BBB
Chenodeoxycholic Acid
Hvidovre University Hospital
Phase 4BBB
Arimidex
Baylor College of Medicine
Phase 4BB
ANHYDROUS MAGNESIUM CARBONATE
San Giuseppe Moscati Hospital
D
ARMICARB
San Giuseppe Moscati Hospital
D

View all 16 →

Same molecule, other indications

Octreotide Pamoate is also rated in:

diarrheal diseaseDormant
BB
Indicative ·
71 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
71 / 100
View asset →
esophageal varicesDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →